By Erik J. MacLaren, PhD The pan-ErbB inhibitor afatinib (Gilotrif) improves progression-free survival (PFS), time-to-treatment-failure (TTF) rate, and objective response rate (ORR) compared to the first-generation EGFR inhibitor gefitinib (Iressa) […] Read more
The International Association for the Study of Lung Cancer (IASLC) and the Oncology Unit of the 3rd Department of Medicine, Medical School of Athens, “Sotiria” Hospital, Greece organized and hosted […] Read more
By Erik J. Mac Laren, PhD In 2015, the US Food and Drug Administration (FDA) approved an unprecedented 7 new drugs or new uses for drugs for patients with lung […] Read more
By Erik J. Mac Laren, PhD In late 2015, the US National Cancer Institute (NCI) Thoracic Malignancy Steering Committee (TMSC) published its strategic priorities for the coming years. These include: […] Read more
By Professor John K. Field MA, PhD, BDS, FRCPath The advent of lung cancer computed tomography (CT) screening was initiated by the Early Lung Cancer Action Project (ELCAP) group in […] Read more
By Emily Stone, MBBS, MMed, FRACP, and Graham Warren, MD, PhD Tobacco control is set to become one of the most clinically effective and rapidly developing areas in lung cancer […] Read more
By Nicola M. Parry, DVM Lung cancer survivor Kathy Weber is an ardent ambassador for the International Association for the Study of Lung Cancer (IASLC). “My involvement with the IASLC […] Read more
By Lori Alexander, MTPW, ELS, MWC How does a person with stage IV lung cancer live a meaningful life? That’s the question Paul Kalanithi explores in When Breath Becomes Air, […] Read more
By Beth Eaby-Sandy, MSN, CRNP, OCN As a nurse practitioner in an academic center in the US, I work in a thoracic medical oncology practice; however, in the US, it […] Read more
By Erik J. MacLaren, PhD The growing number of checkpoint inhibitors currently being developed, without question, has ushered in a new era in clinical oncology, particularly in the treatment of […] Read more